175 related articles for article (PubMed ID: 31594392)
1. Mechanisms by Which Ranolazine Terminates Paroxysmal but Not Persistent Atrial Fibrillation.
Ramirez RJ; Takemoto Y; Martins RP; Filgueiras-Rama D; Ennis SR; Mironov S; Bhushal S; Deo M; Rajamani S; Berenfeld O; Belardinelli L; Jalife J; Pandit SV
Circ Arrhythm Electrophysiol; 2019 Oct; 12(10):e005557. PubMed ID: 31594392
[TBL] [Abstract][Full Text] [Related]
2. Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.
Burashnikov A; Di Diego JM; Barajas-Martínez H; Hu D; Cordeiro JM; Moise NS; Kornreich BG; Belardinelli L; Antzelevitch C
Circ Heart Fail; 2014 Jul; 7(4):627-33. PubMed ID: 24874201
[TBL] [Abstract][Full Text] [Related]
3. Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness.
Milberg P; Frommeyer G; Ghezelbash S; Rajamani S; Osada N; Razvan R; Belardinelli L; Breithardt G; Eckardt L
Europace; 2013 May; 15(5):761-9. PubMed ID: 23376977
[TBL] [Abstract][Full Text] [Related]
4. Ranolazine reduces atrial fibrillatory wave frequency.
Black-Maier EW; Pokorney SD; Barnett AS; Liu P; Shrader P; Ng J; Goldberger JJ; Zareba W; Daubert JP; Grant AO; Piccini JP
Europace; 2017 Jul; 19(7):1096-1100. PubMed ID: 27756767
[TBL] [Abstract][Full Text] [Related]
5. Ranolazine terminates atrial flutter and fibrillation in a canine model.
Bhimani AA; Yasuda T; Sadrpour SA; Khrestian CM; Lee S; Zeng D; Belardinelli L; Waldo AL
Heart Rhythm; 2014 Sep; 11(9):1592-9. PubMed ID: 25066042
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates.
Comtois P; Sakabe M; Vigmond EJ; Munoz M; Texier A; Shiroshita-Takeshita A; Nattel S
Am J Physiol Heart Circ Physiol; 2008 Oct; 295(4):H1489-504. PubMed ID: 18676686
[TBL] [Abstract][Full Text] [Related]
7. Antiarrhythmic Effects of Combining Dofetilide and Ranolazine in a Model of Acutely Induced Atrial Fibrillation in Horses.
Carstensen H; Kjær L; Haugaard MM; Flethøj M; Hesselkilde EZ; Kanters JK; Pehrson S; Buhl R; Jespersen T
J Cardiovasc Pharmacol; 2018 Jan; 71(1):26-35. PubMed ID: 29068807
[TBL] [Abstract][Full Text] [Related]
8. Effects of dofetilide and ranolazine on atrial fibrillatory rate in a horse model of acutely induced atrial fibrillation.
Carstensen H; Hesselkilde EZ; Haugaard MM; Flethøj M; Carlson J; Pehrson S; Jespersen T; Platonov PG; Buhl R
J Cardiovasc Electrophysiol; 2019 Apr; 30(4):596-606. PubMed ID: 30661267
[TBL] [Abstract][Full Text] [Related]
9. Atrial fibrillation characteristics in patients with ischaemic stroke.
Staszewski J
Kardiol Pol; 2007 Jul; 65(7):751-7; discussion 758-9. PubMed ID: 17694456
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiological effects of ranolazine in a goat model of lone atrial fibrillation.
Opačić D; van Hunnik A; Zeemering S; Dhalla A; Belardinelli L; Schotten U; Verheule S
Heart Rhythm; 2021 Apr; 18(4):615-622. PubMed ID: 33232809
[TBL] [Abstract][Full Text] [Related]
11. The mechanical fibrillation pattern of the atrial myocardium is associated with acute and long-term success of electrical cardioversion in patients with persistent atrial fibrillation.
De Vos CB; Limantoro I; Pisters R; Delhaas T; Schotten U; Cheriex EC; Tieleman RG; Crijns HJ
Heart Rhythm; 2014 Sep; 11(9):1514-21. PubMed ID: 24768608
[TBL] [Abstract][Full Text] [Related]
12. Antiarrhythmic properties of ranolazine: A review of the current evidence.
Gupta T; Khera S; Kolte D; Aronow WS; Iwai S
Int J Cardiol; 2015; 187():66-74. PubMed ID: 25828315
[TBL] [Abstract][Full Text] [Related]
13. In vivo characterization of anti-atrial fibrillatory potential and pharmacological safety profile of I
Nunoi Y; Kambayashi R; Goto A; Hagiwara-Nagasawa M; Chiba K; Izumi-Nakaseko H; Kawai S; Takei Y; Matsumoto A; Watanabe Y; Sugiyama A
Heart Vessels; 2021 Jul; 36(7):1088-1097. PubMed ID: 33763729
[TBL] [Abstract][Full Text] [Related]
14. Complexity and Distribution of Drivers in Relation to Duration of Persistent Atrial Fibrillation.
Lim HS; Hocini M; Dubois R; Denis A; Derval N; Zellerhoff S; Yamashita S; Berte B; Mahida S; Komatsu Y; Daly M; Jesel L; Pomier C; Meillet V; Amraoui S; Shah AJ; Cochet H; Sacher F; Jaïs P; Haïssaguerre M
J Am Coll Cardiol; 2017 Mar; 69(10):1257-1269. PubMed ID: 28279292
[TBL] [Abstract][Full Text] [Related]
15. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
[TBL] [Abstract][Full Text] [Related]
16. Fractionation of electrograms and linking of activation during pharmacologic cardioversion of persistent atrial fibrillation in the goat.
Shan Z; Van Der Voort PH; Blaauw Y; Duytschaever M; Allessie MA
J Cardiovasc Electrophysiol; 2004 May; 15(5):572-80. PubMed ID: 15149428
[TBL] [Abstract][Full Text] [Related]
17. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart.
Kumar K; Nearing BD; Carvas M; Nascimento BC; Acar M; Belardinelli L; Verrier RL
J Cardiovasc Electrophysiol; 2009 Jul; 20(7):796-802. PubMed ID: 19298570
[TBL] [Abstract][Full Text] [Related]
18. Serial cardioversion by class IC Drugs during 4 months of persistent atrial fibrillation in the goat.
Eijsbouts S; Ausma J; Blaauw Y; Schotten U; Duytschaever M; Allessie MA
J Cardiovasc Electrophysiol; 2006 Jun; 17(6):648-54. PubMed ID: 16836716
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of atrial fibrillation termination by pure sodium channel blockade in an ionically-realistic mathematical model.
Kneller J; Kalifa J; Zou R; Zaitsev AV; Warren M; Berenfeld O; Vigmond EJ; Leon LJ; Nattel S; Jalife J
Circ Res; 2005 Mar; 96(5):e35-47. PubMed ID: 15731458
[TBL] [Abstract][Full Text] [Related]
20. Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation.
Verrier RL; Silva AF; Bonatti R; Batatinha JA; Nearing BD; Liu G; Rajamani S; Zeng D; Belardinelli L
J Cardiovasc Electrophysiol; 2015 Mar; 26(3):329-35. PubMed ID: 25346368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
